huXBR1-402
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
In Vitro
The antibody-drug conjugate huXBR1-402-G5-PNU inhibits proliferation of ROR1-positive mantle cell lymphoma cells[1].
huXBR1-402 binds to the Ig/Fz domains of human ROR1 with affinity comparable to the parent chimeric antibody XBR1-402[2].
Fully humanized huXBR1-402 specifically binds to human ROR1 expressed on ROR1+ MCL cell lines (JeKo-1, Mino), primary CLL cells[3].
HuXBR1-402 and its antibody-drug conjugate form huXBR1-402-G5-PNU mediate Fc-dependent ADCC and ADCP activity against non-proliferative primary CLL cells, but neither mediates CDC[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
huXBR1-402-G5-PNU (1 mg/kg; i.p.; 3 doses on days 1, 3, and 5 post-randomization; 1 week) increases survival by 3 weeks, stabilizes disease, reduces proliferative leukemic cells, and decreases splenic and peripheral tumor burden in immune competent huROR1-TCL1 CLL mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID (6-8 week old female, immunodeficient, engrafted with human ROR1+ 697 pre-B cell ALL cells)[3]
-
Dosage:1 mg/kg
-
Administration:i.v.; 2 doses (days 7 and 14 post-engraftment)
-
Result:Prolonged survival significantly compared to isotype control trastuzumab-G5-PNU.
-
Animal Model:C57BL/6 (8 week old, immune competent, engrafted with huROR1-TCL1 spleen-derived leukemic cells)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; 3 doses (days 1, 3, and 5 post-randomization); 1 week
-
Result:Increased survival by 3 weeks compared to controls.
Stabilized disease for 3 weeks after the last dose.
Decreased numbers of EdU+ proliferating CD19+/CD5+ leukemic cells in spleens.
Significantly reduced splenic mass.
Almost halved peripheral blood tumor cell counts 4 days before euthanasia compared to vehicle and trastuzumab-G5-PNU controls.
Gene ID
Accession
Q01973
Target
ROR1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
NBE-002 Antibody
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Tigu AB, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov. 2024;10(1):471. Published 2024 Nov 17. [Content Brief]
[2]. Peng H, et al. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther. 2021;4(4):222-227. Published 2021 Oct 15. [Content Brief]
[4]. Wu ZL, et al. Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers. World J Clin Oncol. 2024;15(5):603-613. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)